Dopaminergic dysfunction in tourette syndrome

Harvey S. Singer, Ian J. Butler, Larry E. Tune, William E. Seifert, Joseph T. Coyle

Research output: Contribution to journalArticlepeer-review

Abstract

A prospective clinical and biochemical study on the effects of treatment with haloperidol has been performed in seven patients with Tourette syndrome. Pretteatment cerebrospinal fluid levels of homovanillic acid (CSF HV A) were significantly reduced in all patients, whereas 5‐hydroxyindoleacetic acid was reduced in only two. With haloperidol treatment, symptoms decreased in all cases (21 to 88%) and clinical improvement was associated withan increased level of CSF HV A, often returning to the normal range. Optimal therapeutic response was found with serum levels of haloperidol between 1 and 4 ng/ml; however, disturbing side effects also occurred within this range. These results support the hypothesis that Tourette syndrome may result form a supersensitivity of dopaminergic receptors.

Original languageEnglish (US)
Pages (from-to)361-366
Number of pages6
JournalAnnals of neurology
Volume12
Issue number4
DOIs
StatePublished - Oct 1982

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Dopaminergic dysfunction in tourette syndrome'. Together they form a unique fingerprint.

Cite this